Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
18 Results for "
synovial sarcoma
" in MedChemExpress (MCE) Product Catalog:
Products (18)
18 Results for "synovial sarcoma" in MCE Product Catalog:
2
2 Cited Publications
Research Areas:
FHD-609 is a BRD9 PROTAC degrader. FHD-609 induces BRD9 degradation, downregulates primary transcripts of HBG/HBD, Myc expression and proliferation gene sets, reduces the levels of synovial sarcoma tumor proliferation markers, and inhibits tumor growth. FHD-609 can be used in research related to advanced synovial sarcoma, SMARCB1-deficient tumors and adrenocortical carcinoma .
1
1 Cited Publications
Target:
Research Areas:
CFT8634 is an orally active BRD9 PROTAC degrader with a DC50 of 0.003 μM (HEK293T.166). CFT8634 recruits the CRBN E3 ubiquitin ligase to form a ternary complex, triggering CRBN-catalyzed BRD9 polyubiquitination and 26S proteasome-mediated degradation. CFT8634 induces sustained tumor regression and inhibits tumor growth in mouse models. CFT8634 can be used in research related to synovial sarcoma, SMARCB-1-deficient cancers, acute myeloid leukemia, malignant rhabdoid tumors, and multiple myeloma .
Cat. No.: HY-159579
CAS No.: 3055592-99-6
Target:
Research Areas:
CW-3308 is an orally active BRD9 PROTAC degrader with an DC50 of 92 nM. CW-3308 forms a ternary complex with BRD9 and cereblon to mediate BRD9 degradation. CW-3308 inhibits the viability of synovial sarcoma and rhabdoid tumor cells. CW-3308 reduces BRD9 protein levels in xenograft tumor tissues and suppresses tumor growth in xenograft models. CW-3308 can be used for the research of synovial sarcoma and rhabdoid tumors .
Cat. No.: HY-148739
CAS No.: 2170679-42-0
Target:
Research Areas:
dBRD 9-A is a selective BRD9 PROTAC degrader. dBRD 9-A induces near complete BRD9 degradation dependent on E3 ubiquitin ligase CRBN and BRD9 bromodomain engagement, and drives loss of BRD9 chromatin binding genome-wide. dBRD 9-A downregulates oncogenic SS18-SSX-driven transcriptional programs, super enhancer-associated gene expression, and SS18-SSX1 super enhancer binding, and depletes GBAF complex members GLTSCR1/1L from SS18-SSX complexes. dBRD 9-A induces cell cycle arrest and increases apoptosis in synovial sarcoma cells. dBRD 9-A can be used for the research of synovial sarcoma .
Cat. No.: HY-P99581
CAS No.: 1612758-88-9
Synonyms: OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01
Research Areas:
Target:
Research Areas:
PROTAC BRD9 Degrader-4 is a BRD9 PROTAC degrader with a DC50 of 1 nM. PROTAC BRD9 Degrader-4 is applicable to research related to synovial sarcoma and acute myeloid leukemia .
Cat. No.: HY-P99582
CAS No.: 1644134-10-0
Synonyms: ONC-005, OTSA101
Target:
Research Areas:
Cat. No.: HY-178345
Synonyms: ZZ7
Research Areas:
ZZ7-23-022 (ZZ7) is a selective BRD9 molecule glue degrader. ZZ7-23-022 effectively degrades BRD9 in synovial sarcoma cells, but does not affect cardiomyocytes. ZZ7-23-022 can be used for the research of cancer .
Cat. No.: HY-156401
Target:
Research Areas:
BRD9 Degrader-1 is a selective BRD9 PROTAC degrader with a DC50 of 108 nM. BRD9 Degrader-1 induces the formation of a ternary complex between BRD9 and VHL, with an EC50 of 17 nM, and shows no hook effect at high concentrations. BRD9 Degrader-1 can be used for the research of synovial sarcoma .
Cat. No.: HY-N16372
CAS No.: 1424195-39-0
Category:
Cat. No.: HY-145947
CAS No.: 2704616-86-2
Target:
Research Areas:
PROTAC BRD9 Degrader-5 is a BRD9 PROTAC degrader. PROTAC BRD9 Degrader-5 is used in research on acute myeloid leukemia, rhabdoid tumor, synovial sarcoma, and multiple myeloma .
Target:
Research Areas:
PROTAC BRD9 Degrader-6 (Compound D1) is a racemic PROTAC degrader that recruits cereblon to induce targeted degradation of BRD9. PROTAC BRD9 Degrader-6 has an IC50 of 0.13 nM in SYO-1 cells. It can be used in research on BAF complex-related diseases, such as cancer, infections and synovial sarcoma .
Cat. No.: HY-145925C
CAS No.: 2704617-95-6
Target:
Research Areas:
(S,R)-CFT8634 is a BRD9 PROTAC degrader that exerts activity via the ubiquitin-proteasome pathway. (S,R)-CFT8634 can be used in the research of acute myeloid leukemia, malignant rhabdoid tumor, synovial sarcoma, and multiple myeloma .
Cat. No.: HY-183395
CAS No.: 173374-58-8
FPTI is a SYT-SSX1 fusion protein modulator with selective cytotoxicity in SYT-SSX1-positive synovial sarcoma cells. FPTI down-regulates SYT-SSX1 expression and modulates its downstream target genes. FPTI induces apoptosis in synovial sarcoma cells. FPTI can be used for the research of synovial sarcoma .
Cat. No.: HY-182084
Research Areas:
BRD9 ligand-12 is a BRD9 ligand. BRD9 ligand-12 can be used as a ligand for target protein for PROTAC to develop and design degradative agents for PROTAC BRD9, such as XYD270 (HY-182082). XYD270 inhibits tumor growth in a mouse model of acute myeloid leukemia. XYD270 can be used in research related to synovial sarcoma and acute myeloid leukemia .
Cat. No.: HY-182082
Target:
Research Areas:
XYD270 is an orally active BRD9 PROTAC degrader. XYD270 inhibits the proliferation of cancer cells. XYD270 suppresses tumor growth in a mouse model of acute myeloid leukemia. XYD270 can be used in research related to synovial sarcoma and acute myeloid leukemia .
Cat. No.: HY-150872
Research Areas:
BRD9 ligand-3 is a BRD9 ligand. BRD9 ligand-3 serves as a PROTAC target protein ligand for the synthesis of PROTACs, such as PROTAC BRD9 Degrader-4 (HY-145403). BRD9 ligand-3 is applicable to cancer-related research .
Cat. No.: HY-107446
CAS No.: 2097514-90-2
Research Areas:
BI-7273 acid, BI-7273 (HY-100351) derivative, is a BRD9 PROTAC ligand. BI-7273 acid can be conjugated with E3 ligase Ligand Thalidomide (HY-14658) and linker to synthesize BRD9 PROTAC degrader dBRD 9-A (HY-148739) .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
